{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:52:50Z","timestamp":1772034770047,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Clinical Diagnosis and Treatment New Technology Programs of Jinling Hospital","award":["2023LCZLXA037"],"award-info":[{"award-number":["2023LCZLXA037"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2020YFA0710800"],"award-info":[{"award-number":["2020YFA0710800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["82370733"],"award-info":[{"award-number":["82370733"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04773-y","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T05:10:02Z","timestamp":1757049002000},"page":"999-1006","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights"],"prefix":"10.1007","volume":"58","author":[{"given":"Dandan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genwang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"issue":"10","key":"4773_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","volume":"10","author":"GA Gregory","year":"2022","unstructured":"Gregory GA, Robinson T, Linklater SE et al (2022) Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol 10(10):741\u2013760. https:\/\/doi.org\/10.1016\/S2213-8587(22)00218-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"4773_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2337\/dc17-1118","volume":"41","author":"T Costacou","year":"2018","unstructured":"Costacou T, Orchard TJ (2018) Cumulative kidney complication risk by 50 years of type 1 diabetes: the effects of sex, age, and calendar year at onset. Diabetes Care 41(3):426\u2013433. https:\/\/doi.org\/10.2337\/dc17-1118","journal-title":"Diabetes Care"},{"issue":"8","key":"4773_CR3","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2337\/dc24-0335","volume":"47","author":"P Rossing","year":"2024","unstructured":"Rossing P, Groop PH, Singh R et al (2024) Prevalence of chronic kidney disease in type 1 diabetes among adults in the U.S. Diabetes Care 47(8):1395\u20131399. https:\/\/doi.org\/10.2337\/dc24-0335","journal-title":"Diabetes Care"},{"key":"4773_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108462","volume":"170","author":"P Gillard","year":"2020","unstructured":"Gillard P, Schnell O, Groop PH (2020) The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes. Diabetes Res Clin Pract 170:108462. https:\/\/doi.org\/10.1016\/j.diabres.2020.108462","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"4773_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/S2213-8587(23)00168-7","volume":"11","author":"HJ Heerspink","year":"2023","unstructured":"Heerspink HJ, Cherney DZ, Groop PH et al (2023) People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action. Lancet Diabetes Endocrinol 11(8):536\u2013540. https:\/\/doi.org\/10.1016\/S2213-8587(23)00168-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"20","key":"4773_CR6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP (1993) The effect of Angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329(20):1456\u20131462. https:\/\/doi.org\/10.1056\/NEJM199311113292004","journal-title":"N Engl J Med"},{"issue":"4","key":"4773_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E et al (2018) Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension 71(4):599\u2013608. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10360","journal-title":"Hypertension"},{"key":"4773_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Jaisser F, Kim SY et al (2017) Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 243:271\u2013305. https:\/\/doi.org\/10.1007\/164_2016_76","journal-title":"Handb Exp Pharmacol."},{"issue":"23","key":"4773_CR9","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"issue":"24","key":"4773_CR10","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"4773_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115661","volume":"168","author":"M Sanz-G\u00f3mez","year":"2023","unstructured":"Sanz-G\u00f3mez M, Manzano-Lista FJ, Vega-Mart\u00edn E et al (2023) Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors. Biomed Pharmacother 168:115661. https:\/\/doi.org\/10.1016\/j.biopha.2023.115661","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"4773_CR12","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314(9):884\u2013894. https:\/\/doi.org\/10.1001\/jama.2015.10081","journal-title":"JAMA"},{"issue":"6","key":"4773_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000531997","volume":"9","author":"H Zhang","year":"2023","unstructured":"Zhang H, Xie J, Hao C et al (2023) Finerenone in patients with chronic kidney disease and type 2 diabetes: the FIDELIO-DKD subgroup from China. Kidney Dis (Basel) 9(6):498\u2013506. https:\/\/doi.org\/10.1159\/000531997","journal-title":"Kidney Dis (Basel)"},{"issue":"2","key":"4773_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","volume":"102","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Agarwal R, Alpers CE et al (2022) Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int 102(2):248\u2013260. https:\/\/doi.org\/10.1016\/j.kint.2022.05.012","journal-title":"Kidney Int"},{"key":"4773_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154890","volume":"124","author":"CA Ricciardi","year":"2021","unstructured":"Ricciardi CA, Gnudi L (2021) Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies. Metabolism 124:154890. https:\/\/doi.org\/10.1016\/j.metabol.2021.154890","journal-title":"Metabolism"},{"issue":"1","key":"4773_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","volume":"103","author":"GL Bakris","year":"2023","unstructured":"Bakris GL, Ruilope LM, Anker SD et al (2023) A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int 103(1):196\u2013206. https:\/\/doi.org\/10.1016\/j.kint.2022.08.040","journal-title":"Kidney Int"},{"issue":"1","key":"4773_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad249","volume":"17","author":"FH M\u00e5rup","year":"2024","unstructured":"M\u00e5rup FH, Thomsen MB, Birn H (2024) Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. Clin Kidney J 17(1):sfad249. https:\/\/doi.org\/10.1093\/ckj\/sfad249","journal-title":"Clin Kidney J"},{"issue":"3","key":"4773_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ekir.2023.12.014","volume":"9","author":"ZR Song","year":"2024","unstructured":"Song ZR, Li Y, Zhang H et al (2024) Protective effects of selective mineralocorticoid receptor antagonist in Alport syndrome on top of renin-angiotensin-system\/ sodium-glucose transporter 2 blockade. Kidney Int Rep 9(3):730\u2013731. https:\/\/doi.org\/10.1016\/j.ekir.2023.12.014","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4773_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf157","volume":"18","author":"DD Qiu","year":"2025","unstructured":"Qiu DD, Liu J, Chen RH, Zhang F, An Y, Jiang S (2025) Efficacy and safety of finerenone in obesity-related glomerulopathy. Clin Kidney J 18(6):sfaf157. https:\/\/doi.org\/10.1093\/ckj\/sfaf157","journal-title":"Clin Kidney J"},{"key":"4773_CR20","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"KJ Schjoedt","year":"2005","unstructured":"Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L et al (2005) Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68:2829\u20132836.\u00a0https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00756.x","journal-title":"Kidney Int"},{"key":"4773_CR21","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","volume":"29","author":"SE Nielsen","year":"2012","unstructured":"Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D et al (2012) Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med 29:e184\u201390.\u00a0https:\/\/doi.org\/10.1111\/j.1464-5491.2012.03585.x","journal-title":"Diabet Med"},{"issue":"12","key":"4773_CR22","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","volume":"79","author":"LM Ruilope","year":"2022","unstructured":"Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Sarafidis P, Schmieder RE, Joseph A, Rethemeier N, Nowack C, Bakris GL, Investigators F (2022) Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension 79(12):2685\u20132695. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19744","journal-title":"Hypertension"},{"key":"4773_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110908","volume":"204","author":"H Heerspink","year":"2023","unstructured":"Heerspink H, Birkenfeld AL, Cherney D et al (2023) Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial. Diabetes Res Clin Pract 204:110908. https:\/\/doi.org\/10.1016\/j.diabres.2023.110908","journal-title":"Diabetes Res Clin Pract"},{"key":"4773_CR24","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2337\/dc19-0937","volume":"42","author":"DH van Raalte","year":"2019","unstructured":"van Raalte DH, Bjornstad P, Persson F, Powell DR, de Cassia Castro R, Wang PS et al (2019) The impact of Sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes. Diabetes Care 42:1921\u20131929.\u00a0https:\/\/doi.org\/10.2337\/dc19-0937","journal-title":"Diabetes Care"},{"key":"4773_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","volume":"8","author":"PH Groop","year":"2020","unstructured":"Groop PH, Dandona P, Phillip M, Gillard P, Edelman S, Jendle J et al (2020) Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol 8:845\u2013854.\u00a0https:\/\/doi.org\/10.1016\/S2213-8587(20)30280-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4773_CR26","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.07700621","volume":"16","author":"D Cherney","year":"2021","unstructured":"Cherney D, Bjornstad P, Perkins BA, Rosenstock J, Neubacher D, Marquard J et al (2021) Kidney effects of Empagliflozin in people with type 1 diabetes. Clin J Am Soc Nephrol 16:1715\u20131719.\u00a0https:\/\/doi.org\/10.2215\/CJN.07700621","journal-title":"Clin J Am Soc Nephrol"},{"key":"4773_CR27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","volume":"54","author":"R Kodera","year":"2011","unstructured":"Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M et al (2011) Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54:965\u2013978.\u00a0https:\/\/doi.org\/10.1007\/s00125-010-2028-x","journal-title":"Diabetologia"},{"key":"4773_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ajpath.2012.09.016","volume":"182","author":"A Ojima","year":"2013","unstructured":"Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M et al (2013) Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol 182:132\u2013141.\u00a0https:\/\/doi.org\/10.1016\/j.ajpath.2012.09.016","journal-title":"Am J Pathol"},{"key":"4773_CR29","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E et al (2016) Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT one treat-to-target randomized trial. Diabetes Care 39:1702\u20131710.\u00a0https:\/\/doi.org\/10.2337\/dc16-0691","journal-title":"Diabetes Care"},{"key":"4773_CR30","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2337\/dc16-0690","volume":"39","author":"B Ahr\u00e9n","year":"2016","unstructured":"Ahr\u00e9n B, Hirsch IB, Pieber TR, Mathieu C, G\u00f3mez-Peralta F, Hansen TK et al (2016) Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care 39:1693\u20131701.\u00a0https:\/\/doi.org\/10.2337\/dc16-0690","journal-title":"Diabetes Care"},{"issue":"1","key":"4773_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-023-06015-1","volume":"67","author":"VS Sridhar","year":"2024","unstructured":"Sridhar VS, Limonte CP, Groop PH et al (2024) Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes. Diabetologia 67(1):3\u201318. https:\/\/doi.org\/10.1007\/s00125-023-06015-1","journal-title":"Diabetologia"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04773-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04773-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04773-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:30:53Z","timestamp":1772029853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04773-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4773"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04773-y","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of Jinling Hospital (2022DZKY-069-01) and adhered to the Declaration of Helsinki. All participants provided written informed consent, covering the use of novel therapies and sample collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}